Prime

Type your tag names separated by a space and hit enter

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Abstract

We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. In a heuristic, compassionate use study, we found that 4 of 6 treatment-refractory patients with severe chronic schizophrenia but who had a self-reported history of improving with marijuana abuse improved with dronabinol. This improvement seems to have been a reduction of core psychotic symptoms in 3 of the 4 responders and not just nonspecific calming. There were no clinically significant adverse effects. These results complement the recent finding that the cannabinoid blocker rimonabant does not improve schizophrenic symptoms and suggest that the role of cannabinoids in psychosis may be more complex than previously thought. They open a possible new role for cannabinoids in the treatment of schizophrenia.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Rockland Psychiatric Center, Orangeburg, NY 10962, USA. gs2272@columbia.edu

    ,

    Source

    MeSH

    Adult
    Antipsychotic Agents
    Dronabinol
    Female
    Follow-Up Studies
    Humans
    Male
    Psychiatric Status Rating Scales
    Psychometrics
    Psychotropic Drugs
    Schizophrenia
    Schizophrenic Psychology
    Severity of Illness Index
    Treatment Outcome
    Young Adult

    Pub Type(s)

    Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    19440079

    Citation

    TY - JOUR T1 - Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. AU - Schwarcz,Glenn, AU - Karajgi,Basawaraj, AU - McCarthy,Richard, PY - 2009/5/15/entrez PY - 2009/5/15/pubmed PY - 2009/8/4/medline SP - 255 EP - 8 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 29 IS - 3 N2 - We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. In a heuristic, compassionate use study, we found that 4 of 6 treatment-refractory patients with severe chronic schizophrenia but who had a self-reported history of improving with marijuana abuse improved with dronabinol. This improvement seems to have been a reduction of core psychotic symptoms in 3 of the 4 responders and not just nonspecific calming. There were no clinically significant adverse effects. These results complement the recent finding that the cannabinoid blocker rimonabant does not improve schizophrenic symptoms and suggest that the role of cannabinoids in psychosis may be more complex than previously thought. They open a possible new role for cannabinoids in the treatment of schizophrenia. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/19440079/abstract/Synthetic_delta_9_tetrahydrocannabinol__dronabinol__can_improve_the_symptoms_of_schizophrenia_ L2 - http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=29&issue=3&spage=255 ER -